Leukemia & Lymphoma Society Blood Cancer Discoveries Grant Programme

Closing Date: 28/10/2021

Grant funding for established independent academic investigators to support foundational, discovery-stage research that can lead to advances in the treatment and cure of blood cancers.

The Leukemia & Lymphoma Society (LLS) funds leading-edge research for every type of blood cancer, including leukemia, lymphoma, myeloma, and other rare types of blood cancers.

The Blood Cancer Discoveries Grant Programme (BCDG) is aimed at supporting cutting edge, innovative research that is discovery oriented, concerned with understanding blood cancer properties and vulnerabilities and aimed toward advancing treatments for blood cancers.

Examples of projects of potential interest include:

  • Cellular activities that underlie the behaviour and vulnerabilities of blood cancer cells including phenomena or processes such as clonal evolution, autophagy, unique metabolic vulnerabilities, inflammation/inflammasomes, DNA damage responses, organellar changes, and poorly understood cellular regulatory mechanisms.
  • Resistance mechanisms including immune evasion, resistant clone evolution and cellular changes underlying development of resistance to chemotherapies.
  • Novel biomarkers or techniques to detect and monitor blood cancer development and progression.
  • Discovery of neoantigens, including those that may reside outside of coding regions.
  • Blood cancer cell interactions with the microenvironment and with the immune system, including exploration of novel immune synapses.
Funding body Leukemia & Lymphoma Society (LLS)
Maximum value 750,000 USD
Reference ID S22677
Category Medical Research

Fund or call Fund